Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex

被引:102
作者
Nzula, S
Vandamme, P
Govan, JRW
机构
[1] Univ Edinburgh, Dept Med Microbiol, Edinburgh EH8 9AG, Midlothian, Scotland
[2] State Univ Ghent, Microbiol Lab, B-9000 Ghent, Belgium
关键词
D O I
10.1093/jac/dkf137
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The Burkholderia cepacia complex is a diverse group of human pathogens that cause life-threatening lung infections in patients with cystic fibrosis or chronic granulomatous disease, and in patients requiring intensive care. Most previous antimicrobial susceptibility studies of these bacteria were performed before recent major revisions in the taxonomy of these bacteria. We determined the in vitro susceptibility of 65 B. cepacia complex isolates from clinical and environmental sources, representing six genomovars. Although intrinsic resistance is considered to be a common feature of the B. cepacia complex, MICs of individual antimicrobials varied widely and resistance was not exhibited by all members of the group.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 10 条
[1]   Burkholderia cepacia genomovar III is a common plant-associated bacterium [J].
Balandreau, J ;
Viallard, V ;
Cournoyer, B ;
Coenye, T ;
Laevens, S ;
Vandamme, P .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2001, 67 (02) :982-985
[2]   Taxonomy and identification of the Burkholderia cepacia complex [J].
Coenye, T ;
Vandamme, P ;
Govan, JRW ;
Lipuma, JJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) :3427-3436
[3]   INVITRO ACTIVITIES OF MEROPENEM, PD-127391, PD-131628, CEFTAZIDIME, CHLORAMPHENICOL, COTRIMOXAZOLE, AND CIPROFLOXACIN AGAINST PSEUDOMONAS-CEPACIA [J].
LEWIN, C ;
DOHERTY, C ;
GOVAN, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (01) :123-125
[4]   Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis [J].
LiPuma, JJ ;
Spilker, T ;
Gill, LH ;
Campbell, PW ;
Liu, LX ;
Mahenthiralingam, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (01) :92-96
[5]   Burkholderia cepacia - Management issues and new insights [J].
LiPuma, JJ .
CLINICS IN CHEST MEDICINE, 1998, 19 (03) :473-+
[6]   Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests [J].
MacGowan, AP ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :17-28
[7]   Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex [J].
Mahenthiralingam, E ;
Coenye, T ;
Chung, JW ;
Speert, DP ;
Govan, JRW ;
Taylor, P ;
Vandamme, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :910-913
[8]   Sensitivity of the Burkholderia cepacia complex and Pseudomonas aeruginosa to transducing bacteriophages [J].
Nzula, S ;
Vandamme, P ;
Govan, JRW .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2000, 28 (04) :307-312
[9]   Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains [J].
Parke, JL ;
Gurian-Sherman, D .
ANNUAL REVIEW OF PHYTOPATHOLOGY, 2001, 39 :225-258
[10]   Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland [J].
Pitt, TL ;
Kaufmann, ME ;
Patel, PS ;
Benge, LCA ;
Gaskin, S ;
Livermore, DM .
JOURNAL OF MEDICAL MICROBIOLOGY, 1996, 44 (03) :203-210